AlphaMark Advisors LLC Reduces Position in Haemonetics Co. (NYSE:HAE)

AlphaMark Advisors LLC lessened its holdings in shares of Haemonetics Co. (NYSE:HAE) by 6.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,331 shares of the medical instruments supplier’s stock after selling 229 shares during the quarter. AlphaMark Advisors LLC’s holdings in Haemonetics were worth $276,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of HAE. Westfield Capital Management Co. LP lifted its stake in shares of Haemonetics by 27.2% during the 4th quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier’s stock valued at $60,888,000 after buying an additional 152,098 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Haemonetics by 14.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 191,253 shares of the medical instruments supplier’s stock valued at $16,354,000 after acquiring an additional 24,394 shares during the last quarter. Isthmus Partners LLC bought a new stake in Haemonetics in the 4th quarter valued at $1,530,000. Dynamic Technology Lab Private Ltd bought a new stake in Haemonetics in the 4th quarter valued at $888,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in Haemonetics in the 4th quarter valued at $2,039,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Down 0.2 %

HAE stock traded down $0.15 during trading on Friday, reaching $73.84. 138,868 shares of the stock were exchanged, compared to its average volume of 530,339. The company has a current ratio of 2.56, a quick ratio of 1.50 and a debt-to-equity ratio of 0.83. The business has a 50 day moving average price of $85.44 and a 200-day moving average price of $83.91. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $97.97. The firm has a market capitalization of $3.76 billion, a price-to-earnings ratio of 32.29, a P/E/G ratio of 1.64 and a beta of 0.29.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a return on equity of 22.25% and a net margin of 8.98%. The business had revenue of $336.17 million for the quarter, compared to analysts’ expectations of $335.08 million. During the same period in the previous year, the company earned $1.05 earnings per share. Haemonetics’s quarterly revenue was up 8.0% on a year-over-year basis. On average, research analysts predict that Haemonetics Co. will post 4.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. JMP Securities restated a “market outperform” rating and issued a $125.00 target price on shares of Haemonetics in a report on Tuesday. Barrington Research boosted their target price on shares of Haemonetics from $107.00 to $108.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, Needham & Company LLC upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price target on the stock in a report on Wednesday, June 12th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and an average price target of $109.75.

Insider Buying and Selling

In other Haemonetics news, EVP Anila Lingamneni sold 2,136 shares of the company’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $90.00, for a total transaction of $192,240.00. Following the completion of the transaction, the executive vice president now owns 21,410 shares in the company, valued at approximately $1,926,900. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Haemonetics news, EVP Anila Lingamneni sold 2,136 shares of the firm’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $90.00, for a total transaction of $192,240.00. Following the sale, the executive vice president now directly owns 21,410 shares of the company’s stock, valued at approximately $1,926,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Stewart W. Strong sold 686 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $95.11, for a total transaction of $65,245.46. Following the completion of the transaction, the insider now owns 18,196 shares in the company, valued at approximately $1,730,621.56. The disclosure for this sale can be found here. Insiders sold a total of 29,968 shares of company stock worth $2,663,781 in the last 90 days. Company insiders own 1.80% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.